Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT01670877 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Neratinib
DRUG: Fulvestrant
DRUG: Trastuzumab
PROCEDURE: Tumor biopsy
PROCEDURE: Research blood sample

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]